CEACAM5 and metastatic neoplasm: A Phase II clinical trial with a radiolabeled anti-CEA (carcino embryonic antigen) antibody for the treatment of colorectal cancer patients with liver metastases confirmed early preclinical studies in animal models and suggests the important potential of using TRNT as an adjuvant therapy in the management of metastatic disease [18].